NCT03122067

Brief Summary

The aim of the present experiment is to examine oxytocin's behavioral and neural effects on social pain empathy

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started Jan 2017

Typical duration for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2017

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 17, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 20, 2017

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2018

Completed
Last Updated

February 7, 2018

Status Verified

February 1, 2018

Enrollment Period

1.8 years

First QC Date

April 17, 2017

Last Update Submit

February 6, 2018

Conditions

Healthy

Keywords

oxytocinsocial cognitionfMRIempathy

Outcome Measures

Primary Outcomes (1)

  • Neural activity changes associated with oxytocin administration

    fMRI-assessed brain activity during observing other being socially excluded

    45-60 minutes after drug administration

Secondary Outcomes (1)

  • Behavioral changes associated with oxytocin administration: ball-tossing

    45-60 minutes after drug administration

Study Arms (2)

oxytocin group

EXPERIMENTAL

male participants with oxytocin treatment

Drug: oxytocin treatment

placebo group

PLACEBO COMPARATOR

male participants with placebo treatment

Drug: placebo treatment

Interventions

oxytocin treatmentDRUG

intranasal administration of oxytocin

oxytocin group
placebo treatmentDRUG

intranasal administration of placebo

placebo group

Eligibility Criteria

Age18 Years - 30 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • healthy participants without past or current psychiatric or neurological disorders

You may not qualify if:

  • history of head injury
  • medical or psychiatric illness
  • smoking or drinking 24 hours before experiment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School of Life Science and Technology, University of Electronic Science and Technology of China

Chengdu, Sichuan, 611731, China

RECRUITING

Study Officials

  • Keith Kendrick, Dr.

    School of Life Science and Technology, University of Electronic Science and Technology of China

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Keith Kendrick, Dr.

CONTACT

k.kendrick.uestc@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 17, 2017

First Posted

April 20, 2017

Study Start

January 10, 2017

Primary Completion

October 30, 2018

Study Completion

October 30, 2018

Last Updated

February 7, 2018

Record last verified: 2018-02

Locations

CN(1)